Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Unasnemab - Mitsubishi Tanabe Pharma Corporation/Osaka University

Next Previous
Drug Profile

Unasnemab - Mitsubishi Tanabe Pharma Corporation/Osaka University

Alternative Names: MT-3921

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation; Osaka University
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Anti-inflammatories; Antibodies; Monoclonal antibodies
  • Mechanism of Action RGMA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Spinal cord injuries

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Spinal-cord-injuries in Japan (IV, Infusion)
  • 09 Apr 2025 Mitsubishi Tanabe Pharma America completes phase-II clinical trials in Spinal cord injuries (In adults, In the elderly) in Canada, USA and Japan (IV) (NCT04683848)
  • 28 Dec 2023 Mitsubishi Tanabe Pharma completes phase-I trial in Spinal cord injuries in Japan (IV) (NCT05240612)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top